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Abstract
Background/Aims: The cyclin-dependent kinase 4 (CDK4) participates in the regulation of 
apoptosis of nucleated cells by altering transcriptional regulation of genes governing cell 
proliferation and cell death. Similar to apoptosis of nucleated cells, erythrocytes may enter 
eryptosis, which is characterized by cell shrinkage and cell membrane scrambling with 
phosphatidylserine (PS) exposure at the cell surface. As mature erythrocytes lack nuclei, acute 
stimulation of eryptosis cannot result from altered gene expression. Eryptosis is triggered by 
isotonic cell shrinkage following Cl- removal (replacement with the impermeant organic anion 
gluconate) or by oxidative stress (exposure to 0.3 mM tertbutyl-hydroperoxide [tBOOH]). The 
present study explored whether CDK4 is expressed in erythrocytes and whether the CDK4 
inhibitors II (NSC625987) and III (ryuvidine) influence eryptosis. Methods: Western blotting 
was utilized for determination of the presence of CDK4 protein in human erythrocytes, and 
FACS analysis to determine Fluo3 fluorescence (reflecting cytosolic Ca2+), annexin-V-binding 
(reflecting PS-exposure) and forward scatter (reflecting cell volume). Results: CDK4 protein was 
present in human erythrocytes. Cl- removal was followed by decrease of forward scatter and 
increase of both annexin-V-binding and Fluo3 fluorescence, an effect significantly curtailed 
by CDK4 inhibitors II and III. Furthermore, CDK4 inhibition blunted enhanced PS-exposure 
elicited by tBOOH treatment. Conclusions: The present observations disclose the presence 
of CDK4 protein in human erythrocytes and the suppression of suicidal erythrocyte death by 
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IntroductionThe cyclin-dependent kinase 4 (CDK4) participates in the regulation of cell cycle progression and transcription [1]. Increased activity of cyclin-dependent kinases including CDK4 is observed in cancer and CDK inhibition has been shown to induce G1 arrest and 
apoptosis [2-8]. The efficacy of CDK inhibitors is primarily attributed to altered transcription 
of antiapoptosis family members, cell cycle regulators, as well as p53 and NF-κB-responsive 
gene targets [1, 9]. On the other hand, CDK4 has been implicated in the regulation of neuronal cell death [10]. Activation of CDK4 leads to hyper-phosphorylation of the pRb 
family member p130 with subsequent p130 dissociation from the transcription factor E2F4 
and expression of E2F binding genes including the transcription factors B- and C-Myb, 
which in turn stimulate the expression of the pro-apoptotic BH3-only protein Bim [10]. 
Furthermore, CDK4 is a powerful modulator of mitochondrial functions via phosphorylation 
of mitochondrial targets [11].
Similar to the apoptosis of nucleated cells, erythrocytes are able to undergo suicidal 
death called eryptosis [12, 13]. Triggers of eryptosis include activation of Ca2+-permeable cation channels with Ca2+ entry, activation of Ca2+-sensitive K+ channels, exit of KCl with 
osmotically obliged water and, thus, cell shrinkage. Cytosolic Ca2+ further elicits scrambling 
of the erythrocyte membrane resulting in phosphatidylserine (PS) externalization [13]. 
Extracellular Cl--sensitive osmotic shrinkage opens eryptosis-triggering non-selective cation 
channels in the erythrocyte cell membrane which are also activated by oxidative stress [12]. As 
erythrocytes are devoid of nuclei, any stimulators or inhibitors of eryptosis must be effective 
without influencing gene expression [13].The present study explored whether CDK4 protein is present in erythrocytes and if so, 
whether it influences eryptosis.
Materials and Methods
Erythrocytes, incubations and solutions
Leukocyte-depleted erythrocytes from concentrates were provided by the blood bank of the University of 
Tübingen. The volunteers providing erythrocytes gave informed consent. The study has been approved by the 
Ethical commission of the University of Tübingen. The erythrocytes were incubated at 37°C in Ringer solution 
containing (in mM): 125 NaCl, 5 KCl, 1 MgSO4, and 32 HEPES/NaOH (pH 7.4), 5 glucose, and 1 CaCl2 at a hematocrit 
of 0.4% in a total volume of 1 ml. Where indicated, chloride was replaced by gluconate or 0.3 mM tert-butyl 
hydroperoxide [tBOOH] added to the Ringer solution. The CDK4 inhibitors II (1, 4-Dimethoxyacridine-9(10H)-
thione, NSC 625987) and III (5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole, ryuvidine), 
purchased from Calbiochem (Cat #: 219477 and 219478, Bad Soden, Germany), were dissolved in DMSO and 
added to the respective solutions, at concentrations as indicated. Solvent (0.1%) did not influence annexin V binding (data not shown).
Western blotting
To examine the presence of CDK4 protein in human erythrocytes, 150 µl erythrocyte pellet was lysed 
in 50 ml of 20 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES)/NaOH (pH 7.4). Ghost 
membranes were pelleted (15,000 g for 20 min at 4°C) and lysed in 200 µl lysis buffer (50 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% SDS, 1mM NaF, 1mM Na
3
VO4, 0.4% ß-mercaptoethanol) 
containing protease inhibitor cocktail (Sigma, Taufkirchen, Germany). For whole erythrocyte lysates, 4 µl 
of erythrocytes were lysed in 200 µl lysis buffer. In all cases, 80 µg of protein were solubilized in Laemmli 
sample buffer at 95°C for 5 min and resolved by 10% SDS-PAGE. For immunoblotting, proteins were electro-
transferred onto a PVDF membrane and blocked with 5% nonfat milk in TBS-0.10% Tween 20 (TBST) at 
room temperature for 1 h. Then, the membrane was incubated with monoclonal mouse anti-CDK4 antibody 
(1:2000; 30 kDa, Cell Signaling, Freiburg, Germany) at 4°C overnight. After washing 3 times with TBST (10 
min each), the blots were incubated with horseradish peroxidase conjugated secondary anti-rabbit antibody 
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ECL detection reagent (Amersham, Freiburg, Germany). Antibody-binding was detected with Quantity One 
Software (Biorad, München, Germany).
Determination of phosphatidylserine exposure and forward scatter
For FACS analysis erythrocytes were washed after incubation once in Ringer solution containing 5 mM CaCl2. The cells were then stained with Annexin V-Fluos (Roche, Mannheim, Germany) at a 1:500 dilution. 
After 15 min, samples were measured by flow cytometric analysis (FACS-Calibur from Becton Dickinson; 
Heidelberg, Germany). Cells were analysed by forward scatter, and annexin V-fluorescence intensity 
was measured in fluorescence channel FL-1 with an excitation wavelength of 488 nm and an emission 
wavelength of 530 nm.
Measurement of intracellular Ca2+
After incubation 50 µl suspension erythrocytes were washed in Ringer solution and then loaded with 
Fluo-3/AM (Calbiochem, Bad Soden, Germany) in Ringer solution containing 5 mM CaCl2 and 2 µM Fluo-3/
AM. The cells were incubated at 37°C for 20 min and washed twice in Ringer solution containing 5 mM CaCl2. 
The Fluo-3/AM-loaded erythrocytes were resuspended in 200 µl Ringer. Then, Ca2+-dependent fluorescence 
intensity was measured in fluorescence channel FL-1 in FACS analysis.
Statistics
Data are expressed as arithmetic mean ± SEM, and statistical analysis was made by paired ANOVA with 
Tukey’s test as post-test. Values of p<0.05 were considered statistically significant. n denotes the number of 
different erythrocyte specimens studied.
Results
According to Western blotting, human erythrocytes express the protein kinase CDK4. 
As shown in Fig. 1, the respective bands show the presence of CDK4 protein in membrane 
lysates from isolated human erythrocytes as well as from whole blood. Bands in K562 cell 
lysates were slightly higher presumably due to differential posttranslational modification 
of CDK4 in K562 cells as compared to erythrocytes. Whole cell lysates from isolated human 
erythrocytes further showed CDK4 expression. Further experiments were performed 
to elucidate, whether CDK4 is involved in the regulation of suicidal erythrocyte death or eryptosis.
In a first series of experiments, eryptosis was stimulated by replacement of Cl- with 
gluconate, which leads to profound isosmotic cell shrinkage due to exit of Cl- paralleled by K+ exit. According to forward scatter, which reflects alterations of cell volume, Cl- removal 
was followed by a sharp, significant decrease of cell volume (Fig. 2A and 2B). As shown in 
Fig. 2A and 2B, addition of CDK4 inhibitor II and III did not significantly modify erythrocyte forward scatter in the presence of Cl- ions. However, cell shrinkage following Cl- removal 
was significantly abated by treatment with CDK4 inhibitor III but not by CDK4 inhibitor II 
(Fig. 2A and 2B). Cl- removal is a powerful inducer of PS-externalization on the erythrocyte 
membrane. PS-exposing erythrocytes were identified in FACS analysis utilizing annexin- 
V-binding. To this end, Cl- removal was followed by the expected significant increase in 
annexin-V-binding (Fig. 2C and 2D). Addition of CDK4 inhibitor II did not significantly alter 
PS-exposure in the presence of extracellular Cl- ions but significantly blunted PS-exposure 
CDK4 30 kDa
RBC membrane Whole blood 
membrane isolates
K562 Whole RBCs
Fig. 1. Presence of CDK4 in human 
erythrocytes. Original Western 
blots demonstrating the presence 
of CDK4 (30 kDa) protein in mem-
branes from isolated human eryth-
rocytes and from whole blood as 
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in the absence of Cl- ions, an effect reaching statistical significance at a concentration of 5 
µM (Fig. 2C). Similarly, the CDK4 inhibitor III did not significantly modify PS-exposure in the presence of extracellular Cl- ions but significantly attenuated PS-exposure in the absence of Cl- ions, an effect reaching statistical significance at a concentration of 0.2 µM (Fig. 2C).
Enhanced PS-exposure following Cl- removal is known to be stimulated by nonselective cation channels which elicit increased cytosolic Ca2+ activity in erythrocytes. Thus, Fluo3 
fluorescence was employed to determine erythrocyte Ca2+. As shown in Fig. 3A and 3B, Cl- 
removal significantly increased Fluo3 fluorescence. Treatment with CDK4 inhibitors II and 
III did not significantly modify Fluo 3 fluorescence in the presence of extracellular Cl- ions 
but markedly blunted the increase of Fluo3 fluorescence following Cl- removal, an effect 
reaching statistical significance at 5 µM and 0.2 µM concentration respectively for inhibitors 
II and III (Fig. 3A and 3B).
Additional series of experiments explored the effect of pharmacological inhibition of 
CDK4 on eryptosis triggered by oxidative stress, which was accomplished by exposure of 
erythrocytes for 30 minutes to 0.3 mM of the oxidant tert-butyl-hydroperoxide (tBOOH). 
As illustrated in Fig. 4, exposure to tBOOH (0.3 mM) was followed by a sharp, significant 
increase in erythrocyte PS-exposure. The addition of CDK4 inhibitors II and III again did 
not significantly modify PS-exposure in the absence of tBOOH, but significantly curtailed 
PS-exposure in the presence of tBOOH indicating the efficacy of CDK4 inhibitors II and III in 
curtailing eryptosis triggered by oxidative stress (Fig. 4).
Fig. 2. Effect of CDK4 inhibitors on erythrocyte cell shrinkage and phosphatidylserine externalization fol-lowing extracellular Cl- removal. (A, B) Means ± SEM of forward scatter geomean determined in erythro-cytes incubated for 48 h in Ringer solution (left bars) or chloride-free Ringer solution (right bars) in the 
absence (Control) or in the presence of 0.5 – 5 µM CDK4 inhibitor II (A, gray bars, n=13) or 0.2 – 5 µM CDK4 
inhibitor III (B, black bars, n=16). *** significant (p<0.001) from the presence of Cl- ions. ### significant 
(p<0.001) from the absence of inhibitor. (C, D) Means ± SEM of PS-exposure determined in erythrocytes incubated for 48 h in Ringer solution (left bars) or chloride-free Ringer solution (right bars) in the absence 
(Control) or in the presence of 0.5 – 5 µM CDK4 inhibitor II (C, gray bars, n=13) or 0.2 – 5 µM CDK4 inhibitor 
III (D, black bars, n=16). *, *** significant (p<0.05, p<0.001) from the presence of Cl- ions. #, ### significant 
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DiscussionThe present observations reveal that the protein kinase CDK4 protein is present in 
human erythrocytes and that the CDK4 inhibitors II and III significantly interfere with the 
stimulation of eryptosis following Cl- depletion and oxidative stress.
Both oxidative stress and removal of extracellular Cl- ions are known to foster increase in cytosolic Ca2+ activity [12, 13]. Herein, we observed that both CDK4 inhibitors II and III 
thwart eryptosis by mitigating the increase of cytosolic Ca2+ activity following removal of extracellular Cl- ions. Beyond the activation of scramblase and Ca2+-sensitive K+ channels 
[12], enhanced cytosolic Ca2+ activity participates in the modification of the cytoskeleton and in the activation of a wide variety of Ca2+-sensitive enzymes such as transglutaminase 
[14], phospholipases [15], calpain [14], protein kinases and phosphatases [16, 17]. Calpain 
activation is responsible for the membrane blebbing during suicidal erythrocyte death [12].
Recently, hematopoiesis was shown to be affected in mice with a combined deficiency 
of CDK2 and CDK4 [18]. Interestingly, the combined deficiency of these cyclin-dependent 
kinases resulted in increased erythrocyte cell volume [18]. The CDK4 inhibitors used 
in this study are chemically unrelated compounds which have previously been shown to 
Fig. 3. Effect of CDK4 inhibitors on erythrocyte cytosolic Ca2+ activity following extracellular Cl- removal. (A, 
B) Means ± SEM of Fluo3 geomean determined in erythrocytes incubated for 48 h in Ringer solution (left 
bars) or chloride-free Ringer solution (right bars) in the absence (Control) or in the presence of 0.5 – 5 µM 
CDK4 inhibitor II (A, gray bars, n=4) or 0.2 – 5 µM CDK4 inhibitor III (B, black bars, n=13). *, *** significant 
(p<0.05, p<0.001) from the presence of Cl- ions. #, ### significant (p<0.05, p<0.001) from the absence of inhibitor.
Fig. 4. Effect of CDK4 inhibitors on erythrocyte 
phosphatidylserine externalization following oxi-
dant treatment. Means ± SEM (n=3-7) of PS-expo-
sure determined in erythrocytes incubated for 30 
min in Ringer solution (left bars) or in Ringer solu-
tion containing 0.3 mM tBOOH (right bars) in the 
absence (Control) or in the presence of 5 µM CDK4 
inhibitor II (gray bars) or 5 µM CDK4 inhibitor III 
(black bar). *** significant (p<0.001) from the ab-
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potently inhibit CDK4 kinase activity. CDK4 inhibitor II (NSC 625987) is an ATP-competitive 
thioacridone compound and has been shown to possess a greater selectivity for CDK4 over 
other cyclin-dependent kinases including CDK1 and CDK2 [19]. On the other hand, the 
dioxobenzothiazole compound CDK4 inhibitor III (ryuvidine) was reported to suppress 
CDK4 activity by a higher magnitude as compared to CDK2 kinase [20]. In the present study, 
we have shown that CDK4 protein is present in human erythrocytes and pharmacological 
inhibition of CDK4 modulates eryptosis. The broad spectrum of kinase inhibition elicited by 
these inhibitors and off-target effects, nevertheless, warrants further investigation to clarify the putative role of CDK4 kinase in erythrocyte survival. A wide variety of erythrocyte-
expressed kinases further participate in the eryptosis machinery such as AMPK [21], CK1α 
[22], Janus kinase 3 [23], p38 MAPK [24] and PAK2 [25]. Whether these kinases influence 
CDK4 activity during eryptosis remains to be shown.
Oxidative stress is a pathophysiologically relevant trigger of suicidal erythrocyte death 
in vivo as many clinical conditions with enhanced eryptosis are also associated with redox 
imbalance [26, 27]. Animal experiments have confirmed that erythrocytes subjected to oxidative stress have reduced lifespan in vivo and are rapidly cleared from the circulation 
[28]. Interestingly, cellular redox balance is decisive in the regulation of cyclin-dependent 
kinase-sensitive cell cycle [29] which fosters the convergence of different cell cycle signaling 
pathways on regulators of cyclin-dependent kinase activity such as p16, p27, and cyclin D1 
[30, 31]. Due to the absence of key organelles, nucleus and mitochondria, it is not known 
whether these mechanisms could similarly be operative in erythrocytes.
Noticeably, we observed that the CDK4 inhibitors attenuated oxidant-induced eryptosis 
with different efficacies in contrast to the inhibition of eryptosis following removal of extracellular Cl- ions. According to our data, CDK4 inhibitor III showed a more robust 
amelioration of cytosolic Ca2+ activity as compared to inhibitor II following removal of extracellular Cl- ions. Removal of Cl- ions triggers PGE2 release which, in turn is associated 
with activation of non-selective cation channels and subsequent upregulation of cytosolic Ca2+ activity [32]. On the other hand, oxidative stress, in addition to enhanced cytosolic Ca2+ 
activity, is also associated with activation of caspases [27] and [33]. It is, therefore, possible 
that the CDK4 inhibitors II and III differentially target these mechanisms, independently 
of CDK4 kinase inhibition, in mitigating eryptosis due to oxidative stress or removal of extracellular Cl- ions.
Eryptosis is enhanced by erythrocyte age [34], and is triggered by a wide variety of 
anemia-causing xenobiotics and endogeneous substances [35-48]. Furthermore, eryptosis 
participates in the pathophysiology of several clinical disorders such as iron deficiency, 
hepatic failure, chronic kidney disease, sepsis, malignancy, Wilson’s disease and presumably 
metabolic syndrome [12, 13, 49-51]. Eryptosis may further influence erythrocytes stored 
for transfusion [52]. Eryptotic erythrocytes are rapidly phagocytosed and cleared from 
circulating blood, thus enhancing the risk of anemia [12]. Eryptosis further stimulates blood 
clotting [53] and may compromise microcirculation by increased adhesion of eryptotic 
erythrocytes to the vascular wall [54].
In conclusion, the present observations demonstrate that erythrocytes express CDK4 
and provide evidence that pharmacological CDK4 inhibition interferes with suicidal erythrocyte death.
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